CTS implement the Bio-Rad Geenius HIV 1/2 supplemental assay on Monday September 21, 2020. The newly licensed Geenius test is an immunochromatographic assay designed to confirm and differentiate individual antibodies to Human Immunodeficiency Virus Types 1 and 2. The assay will be replacing the HIV-1 Western blot and HIV-2 EIA assays which are performed on samples with a reactive result on a licensed HIV 1/2 screening test.
Read all about it on the Communication page by clicking this link: Communications
IPFA welcomes Marion Lanteri as Executive Board member, CTS as new member organization
In July, all 5 CTS laboratories will convert from the current Grifols Ultrio Plus NAT triplex assay ...
CTS originally communicated that Tampa will convert from the current Grifols Ultrio Plus NAT triplex...
On August 9, 2019, the new CTS Laboratory Information System was successfully implemented in St...
The recent communication regarding the recent Anti-SARS-CoV-2 Total assay in Tampa has brought about...
As a reminder, CTS will be exhibiting this weekend at the AABB Annual Meeting in San Antonio, T...